科研之友
微信
新浪微博
Facebook
分享链接
摘要
Reasons for performing studyThe mechanism of hyperthermia, a potentially fatal adverse effect of erythromycin treatment of foals, is unknown. ObjectivesTo determine the cause of erythromycin-associated hyperthermia. It was hypothesised that the normal sweat response of foals is impaired by treatment with erythromycin. Study designBlinded, crossover study in 10 healthy pony foals. MethodsFoals kept in stalls were given either erythromycin (25mg/kg bwt orally, 3 times daily) or control for 10days then turned out for a further 10days. Quantitative intradermal terbutaline sweat tests were performed on Days 1 (baseline), 3, 10 and 20. The effects on terbutaline-induced sweating of erythromycin, terbutaline concentration and treatment day were analysed by repeated-measures ANOVA with Bonferroni-corrected pairwise post hoc comparisons. Peak temperatures were compared by Wilcoxon's signed rank test and proportions by McNemar's related samples test. Significance was set at P<0.05. ResultsThere were significant 2-factor interactions for treatment x terbutaline after baseline, treatment x day at every terbutaline concentration, and day x terbutaline for erythromycin (P<0.001) but not control (P=0.9) treatment. Sweating was significantly reduced from baseline in erythromycin-treated foals at all subsequent days. Erythromycin-treated foals produced less sweat at all time-points than did control-treated foals (P<0.05). Peak rectal temperatures of erythromycin-treated foals were significantly higher (P=0.02) than those of controls. During the first 3days outside more erythromycin-treated than control-treated foals required treatment for hyperthermia (6 vs. 0; P=0.03). ConclusionsWe believe drug-induced anhidrosis is the likely cause of hyperthermia in some foals treated with erythromycin.
- 出版日期2016-9
